Kailera Therapeutics Raises $600 Million
Kailera Therapeutics, an obesity drug startup, has secured $600 million in funding from investors, marking one of the largest private financing rounds for a biotech company this year.
The financing round was led by Bain Capital's private equity group and included investments from Royalty Pharma, the sovereign wealth fund in Qatar, and the asset manager of Canada's national pension plan, as well as several of Kailera's founding investors.
This deal highlights the ongoing interest in weight loss drugs, despite some clinical disappointments in recent years. Kailera's Series B round comes almost exactly one year after the startup launched with $400 million and follows Pfizer's announcement to acquire another obesity drug developer, Metsera, for $4.9 billion.
Kailera's funding underlines the persistent attention being paid to weight loss drugs.
The company's significant funding will likely contribute to the development of new obesity treatments, building on the momentum of recent investments in the field.
Author's summary: Kailera Therapeutics raises $600 million for obesity drug development.